ENTPD1 and rheumatoid arthritis: At baseline, the percentage of B CD39+CD73+ cells tended to be lower in R-RA patients compared to NR-RA patients (p = 0.07), and this difference became statistically significant after 3 months of treatment (p = 0.050).